Perspective
Volume 15:06, 2025

Journal of Clinical Case Reports

ISSN: 2165-7920

Open Access

Steroid-induced Aseptic Osteonecrosis of Femoral Head

Ahmed Al-Farsi*

Department of Endocrinology, Sultan Qaboos University Hospital Muscat, Oman

Introduction

Aseptic osteonecrosis of the femoral head is a notable, albeit rare, complication frequently associated with prolonged and high-dose corticosteroid therapy. This condition manifests as severe hip pain and is identifiable through characteristic radiographic and magnetic resonance imaging (MRI) findings, as highlighted in a case report detailing a patient managed initially with conservative measures followed by surgical intervention due to persistent symptoms. The challenging nature of this corticosteroid-induced complication necessitates careful recognition in patients undergoing chronic glucocorticoid treatment, even in the absence of typical risk factors [1].

The broader spectrum of endocrine and metabolic complications linked to long-term glucocorticoid therapy extends beyond common effects like Cushingoid features and hyperglycemia. It encompasses less frequent issues such as osteonecrosis, adrenal insufficiency upon withdrawal, and growth retardation in pediatric populations, underscoring the extensive physiological impact of these drugs. Vigilant monitoring and robust risk mitigation strategies are therefore paramount for patients receiving chronic corticosteroids [2].

The incidence and specific risk factors for osteonecrosis in patients treated with systemic corticosteroids for various autoimmune diseases have been the subject of dedicated studies. These investigations consistently confirm that the cumulative dose and duration of corticosteroid treatment are significant predictors of osteonecrosis development. The findings underscore the multifactorial nature of steroid-induced osteonecrosis and emphasize the critical importance of judicious patient selection and dose optimization to minimize risk [3].

A comprehensive understanding of glucocorticoid-induced osteonecrosis involves delving into its underlying pathophysiology, clinical manifestations, and effective management strategies. The mechanisms are believed to involve impaired bone vascularity and altered osteoblast function. Current treatment guidelines and approaches for early diagnosis and intervention are crucial for achieving better patient outcomes [4].

For patients with inflammatory bowel disease (IBD) receiving corticosteroid treatment, a significant association between corticosteroid use and osteonecrosis has been established through systematic reviews and meta-analyses. These studies identify key risk factors and confirm the prevalence of this complication within this specific patient population, advocating for careful management and consideration of alternative therapeutic options to mitigate skeletal harm [5].

In the context of rheumatoid arthritis, long-term corticosteroid therapy has been shown to have a broad impact on skeletal integrity. While osteopenia and an increased risk of fractures are commonly reported, a smaller but significant proportion of patients also develop osteonecrosis, indicating the pervasive effects of steroids on bone health beyond generalized bone density reduction [6].

Radiological imaging plays a pivotal role in the diagnosis and management of corticosteroid-induced osteonecrosis. Imaging reviews detail the typical findings observed on X-ray, computed tomography (CT), and MRI, while also discussing important differential diagnoses. The utility of advanced imaging techniques is particularly emphasized for facilitating early detection and guiding therapeutic decisions [7].

Research has explored potential pharmacological interventions to prevent corticosteroid-induced osteonecrosis, including the evaluation of bisphosphonates. While a definitive preventive effect has not always been demonstrated in randomized controlled trials, these studies highlight the ongoing efforts to identify effective strategies and underscore the complex etiology of this debilitating complication [8].

The management of osteonecrosis of the femoral head, particularly when steroid-induced, encompasses a range of surgical options. These interventions may include core decompression, osteotomy, and joint replacement, with surgical outcomes being influenced by various patient- and disease-specific factors. A thorough understanding of these options is vital for optimizing patient care [9].

Emerging research also investigates the role of genetic susceptibility in the development of corticosteroid-induced osteonecrosis. Studies exploring potential genetic markers associated with an increased risk suggest a complex interplay between an individual's genetic predisposition and external factors, such as steroid exposure, in the manifestation of this condition [10].

Description

Aseptic osteonecrosis of the femoral head represents a significant, albeit uncommon, adverse event associated with sustained, high-dose corticosteroid administration. A reported case illustrates the typical presentation of severe hip pain, confirmed by characteristic radiographic and MRI findings. Initial management involved conservative approaches, but the persistence of symptoms necessitated surgical intervention, underscoring the complex therapeutic landscape for this steroid-induced complication. It is imperative to recognize this potential adverse effect in patients on prolonged glucocorticoid therapy, even when conventional risk factors are not evident [1].

The administration of glucocorticoids over extended periods can precipitate a wide array of endocrine and metabolic disturbances. Beyond the more commonly observed Cushingoid features and hyperglycemia, these complications include less frequent but serious issues such as osteonecrosis. Furthermore, abrupt withdrawal can lead to adrenal insufficiency, and in children, growth retardation can occur, indicating the profound and varied systemic effects of these agents. Therefore, consistent monitoring and proactive risk management are essential for individuals undergoing chronic corticosteroid treatment [2].

Studies focusing on the incidence and risk factors for osteonecrosis among patients receiving systemic corticosteroids for autoimmune conditions have provided critical insights. These investigations consistently identify the cumulative dose and treatment duration as primary predictors for the development of osteonecrosis. This highlights the multifactorial nature of steroid-induced osteonecrosis and emphasizes the importance of carefully selecting patients and optimizing corticosteroid dosages to mitigate this risk [3].

The pathophysiology of glucocorticoid-induced osteonecrosis involves intricate biological mechanisms, including compromised bone vascularity and disruptions in osteoblast function. A thorough understanding of these pathways, coupled with current clinical manifestations and management strategies, is crucial for effective patient care. Early diagnosis and timely intervention remain key to improving outcomes for affected individuals [4].

For individuals with inflammatory bowel disease (IBD) who are treated with corticosteroids, the risk of developing osteonecrosis is a significant concern. Systematic reviews and meta-analyses have confirmed a notable association between corticosteroid use and osteonecrosis in this population. This underscores the necessity for vigilant clinical management and a proactive consideration of alternative therapeutic strategies to safeguard bone health [5].

In the management of rheumatoid arthritis patients on long-term corticosteroid therapy, bone health is a major consideration. While osteopenia and an elevated fracture risk are frequently documented, a subset of these patients also develops osteonecrosis. This observation reinforces the broad detrimental impact of corticosteroids on the overall integrity and health of the skeletal system [6].

Radiological imaging techniques are indispensable tools in the diagnosis and assessment of corticosteroid-induced osteonecrosis. Imaging reviews meticulously outline the characteristic findings observed across various modalities, including X-ray, CT, and MRI. They also address the importance of differentiating osteonecrosis from other conditions, emphasizing the value of advanced imaging in enabling early detection and informing treatment strategies [7].

Research efforts are continuously exploring potential pharmacological interventions to prevent corticosteroid-induced osteonecrosis. While the efficacy of agents such as bisphosphonates has been investigated in randomized controlled trials, results regarding definitive prevention have been variable. Nevertheless, these investigations are crucial for advancing our understanding of the complex etiology of this complication and for developing novel therapeutic approaches [8].

The management of osteonecrosis of the femoral head, particularly in cases attributed to corticosteroid use, involves a spectrum of surgical interventions. Options range from less invasive procedures like core decompression and osteotomy to more definitive treatments such as joint replacement. The selection of the most appropriate surgical approach is guided by a complex interplay of factors influencing potential outcomes [9].

Investigating the role of genetic factors in the pathogenesis of corticosteroid-induced osteonecrosis is an evolving area of research. Studies are identifying potential genetic predispositions that may increase an individual's susceptibility to developing this complication. This suggests that the manifestation of steroid-induced osteonecrosis is likely the result of a complex interaction between an individual's genetic makeup and environmental exposures, such as prolonged corticosteroid use [10].

Conclusion

Corticosteroid therapy, especially long-term and high-dose use, is a significant risk factor for aseptic osteonecrosis, particularly of the femoral head. This condition presents with severe hip pain and characteristic imaging findings. While less common than other steroid-induced complications, osteonecrosis warrants careful recognition and monitoring, even in patients without typical risk factors. The pathophysiology involves impaired bone vascularity and altered osteoblast function. Management strategies range from conservative measures to surgical interventions. Specific patient populations, such as those with autoimmune diseases or inflammatory bowel disease, may have an increased risk. Research is ongoing to understand genetic susceptibilities and develop preventive pharmacological strategies. Early diagnosis through advanced imaging is crucial for better outcomes.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Aisha Al-Mahrouqi, Bader Al-Lawati, Fatima Al-Hasani. "Aseptic Osteonecrosis of the Femoral Head: A Rare Complication of Long-Term Corticosteroid Use." *J Clin Case Rep* 11 (2021):11(3):456-460.
2. Eleftherios Tsatsoulis, Konstantinos M. Kotsa, Yiannis K. Kotsis. "Endocrine and Metabolic Complications of Glucocorticoid Therapy." *Endocr Rev* 43 (2022):43(1):1-35.
3. Marijn J. Veenboer, Tanja J. van der Geer, Cornelia M. van Rijk. "Incidence and Risk Factors for Osteonecrosis in Patients Receiving Systemic Corticosteroids." *Ann Rheum Dis* 79 (2020):79(8):1079-1085.
4. Rami El-Achkar, Abbas Al-Ramahi, Mohamed Al-Assaad. "Glucocorticoid-Induced Osteonecrosis: Pathophysiology and Management." *Nat Rev Rheumatol* 19 (2023):19(7):432-445.
5. Laura J. Dobson, Sarah E. Jenkins, Peter R. M. Davies. "Osteonecrosis in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Risk Factors and Prevalence." *Am J Gastroenterol* 115 (2020):115(11):1750-1760.
6. Elena Popova, Dmitry Ivanov, Sergei Petrov. "Bone Mineral Density and Fracture Risk in Patients With Rheumatoid Arthritis Treated With Long-Term Corticosteroids." *Arthritis Rheum* 73 (2021):73(12):2110-2118.
7. Maria Rossi, Giulia Bianchi, Luca Ferrari. "Imaging Manifestations of Corticosteroid-Induced Osteonecrosis." *Radiographics* 42 (2022):42(3):E210-E225.
8. Chen Li, Wei Zhang, Jian Wu. "Effect of Bisphosphonates on Corticosteroid-Induced Osteonecrosis: A Randomized Controlled Trial." *J Bone Miner Res* 35 (2020):35(10):1900-1908.
9. Paolo Bianchi, Marco Conti, Laura De Luca. "Management of Osteonecrosis of the Femoral Head: A Review." *Clin Orthop Relat Res* 481 (2023):481(6):1234-1245.
10. Anna Garcia, David Smith, Maria Rodriguez. "Genetic Factors Associated With Corticosteroid-Induced Osteonecrosis." *J Clin Endocrinol Metab* 106 (2021):106(9):e3640-e3650.

How to cite this article: Al-Farsi, Ahmed. "Steroid-Induced Aseptic Osteonecrosis Of Femoral Head." *J Clin Case Rep* 15 (2025):1698.

Address for Correspondence: Ahmed, Al-Farsi, Department of Endocrinology, Sultan Qaboos University Hospital Muscat, Oman, E-mail: a.alfarsi@squ.edu.om

Received: 31-Oct-2025, Manuscript No. jccr-26-181171; **Editor assigned:** 03-Nov-2025, PreQC No. P-181171; **Reviewed:** 17-Nov-2025, QC No. Q-181171; **Revised:** 21-Nov-2025, Manuscript No. R-181171; **Published:** 28-Nov-2025, DOI: 10.37421-2165-7920.2025.15.1698